Billionaire Bill Ackman Funds $400M Brain Institute to Save His Daughter
Billionaire Bill Ackman is investing over $400 million to launch a brain research institute after his daughter Lucy suffered a severe brain hemorrhage. The project follows a historic FDA emergency clearance for experimental cell therapy.
A Family Tragedy Sparks Scientific Action
The life of Jewish-American billionaire and hedge fund manager Bill Ackman was upended last February when his 26-year-old daughter, Lucy, collapsed in her Brooklyn apartment following a severe brain hemorrhage. The medical emergency left her paralyzed, blind, and unable to speak.
This devastating crisis prompted Ackman to mobilize every financial and medical resource at his disposal. His efforts led to a historic milestone: securing a first-of-its-kind emergency clearance from the U.S. Food and Drug Administration (FDA) for an experimental cellular therapy targeting her eyes.
Alongside the fight for his daughter's recovery, Ackman has announced the establishment of a massive institute dedicated to brain research, rehabilitation, and longevity, backed by an unprecedented investment of over $400 million, as first reported by The Washington Post.
Experimental Mitochondrial Therapy
Immediately following the incident, Lucy was admitted to Mount Sinai Health System in New York. At the recommendation of a research team led by neurobiologist Dr. David Putrino, the medical staff petitioned the FDA for emergency authorization to perform a mitochondrial transplant. Mitochondria function as the primary energy-producing powerhouses within human cells.
The procedure involved extracting mitochondria from a muscle in Lucy's leg and injecting them directly into her eyes to regenerate damaged optic nerves. Initial trials yielded temporary improvement, allowing Lucy to perceive light for the first time. However, the effect faded after about a month, and the medical team is currently working on increasing the frequency of the injections.
The experimental treatment has generated significant interest as well as skepticism within the scientific community. While mitochondria are recognized as key players in cellular repair and anti-aging, researchers question whether micro-injections can survive and effectively influence a biological system requiring trillions of cells.
Launching the Ackman-Oxman Institute
In response to the medical challenge, Ackman and his Israeli wife, Neri Oxman, announced the founding of the Ackman-Oxman Institute (AOI). The goal is to build the world's premier center for brain rehabilitation and life extension. The institute's board already includes a Nobel laureate, prominent neuroscientists, and the CEO of Regeneron Pharmaceuticals.
Ackman's initiative aligns with a broader trend among the American financial and tech elite. Figures like Jeff Bezos, Sam Altman, Peter Thiel, and Elon Musk are channeling hundreds of millions of dollars into private longevity research and brain-computer interfaces.
This shift is accelerating amid a 15% reduction in federal research grants from the National Institutes of Health (NIH) and staff departures at the FDA under the second administration of U.S. President Donald Trump, prompting private donors to step in and fund cutting-edge science.
Political Shift and Academic Recruitment
Ackman, formerly a prominent donor to the Democratic Party, has undergone a significant political shift to the right in recent years. The turning point began with what he viewed as Harvard University's weak response to the October 7, 2023, massacre by Hamas terrorists.
This led Ackman to launch a high-profile public campaign resulting in the resignation of Harvard's then-president Claudine Gay, alongside sharp criticism of campus diversity programs and antisemitism. Through this activism, he connected with tech leaders and human optimization advocates who supported his medical endeavors.
According to Ackman, the academic crisis surrounding campus politics and antisemitism allowed him to acquire real estate and recruit top-tier researchers disillusioned with institutional academia. He emphasized that the new institute will focus on developing rapid, practical treatments for patients rather than publishing theoretical papers. As Lucy continues her long rehabilitation, her family's private struggle is shining a global spotlight on the frontier of cellular medicine.
